Get started
Author

Vicente Guillem Porta

Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study
2004 · M.F. Avril, S. Aamdal, et al. · Journal of Clinical Oncology · 495
Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy
2005 · Luca Gianni, José Baselga, et al. · Clinical Cancer Research · 166
Phase II trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer
2012 · Antonio Llombart-Cussac, Ángel Guerrero, et al. · Clinical & Translational Oncology · 71
European Cooperative Trial in Operable Breast Cancer (ECTO): Improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF)
2005 · L. Gianni, J. Baselga, et al. · Journal of Clinical Oncology · 66
Breakthrough cancer pain: review and calls to action to improve its management
2020 · C. Camps Herrero, N. Batista, et al. · Clinical & Translational Oncology · 32
Oncologist’s knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study
2017 · R. López López, C. Camps Herrero, et al. · Clinical & Translational Oncology · 24
Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP)
2018 · C. Camps Herrero, J. J. Reina Zoilo, et al. · Clinical & Translational Oncology · 15
Long term survival of vinorelbine (N) and trastuzumab (H) as first line therapy for HER2-positive metastatic breast cancer patients (HER2+MBC) (pts)
2005 · A. Chan, L. Petruzelka, et al. · Journal of Clinical Oncology · 10
Evaluation of vinorelbine (N) and trastuzumab (H) as first-line therapy for patients (pts) with HER2- positive metastatic breast cancer (HER2+ MBC): Impact on clinical response and cardiac function
2004 · V. Guillem Porta, M. Martin, et al. · Journal of Clinical Oncology · 8
Manual de oncología clínica
2000 · V. Guillem Porta · Clinical & Translational Oncology · 5
Criteria and indicators to evaluate quality of care in genitourinary tumour boards
2024 · Javier Puente, Ferrán Algaba Arrea, et al. · Clinical & Translational Oncology · 3
Anti-emetic efficacy of oral granisetron in the total control of late-onset emesis induced by cyclophosphamide-containing chemotherapy
2004 · Enrique Aranda Aguilar, Vicente Guillem Porta, et al. · Revista de Oncología · 2
Avances en oncología
2002 · V. Guillem Porta · Dialnet (Universidad de la Rioja) · 2
Measures to evaluate quality of care in renal cancer: results of a Delphi study in Spain
2021 · Vicente Guillem Porta, Carlos Camps, et al. · Clinical & Translational Oncology · 1
PDF
Treatment Patterns of Adjuvant Interferon Alfa-2B (Ifn-&Agr;2B) for High-Risk Melanoma. a Retrospective Study of the Grupo Español Multidisciplinar De Melanoma (Gem)
2014 · S. Martin-Algarra, V. Soriano, et al. · Annals of Oncology · 1
PDF
1869P Pain in cancer: The patient experience in Spain
2020 · J. Garcia-Foncillas, A. Anton, et al. · Annals of Oncology
Clinical practice evaluation of opioids induced constipation management in cancer patients: The EIO-Praxis project
2019 · E. Aranda Aguilar, J. Garcia Foncillas, et al. · Annals of Oncology
PDF
The quality oncology practice initiative program: Experience in Spain
2018 · R. Lopez Lopez, A. Anton Torres, et al. · Annals of Oncology
Assessment and treatment of breakthrough cancer pain in Spain: A self-audit study
2018 · R. Lopez Lopez, J.J. Reina Zoilo, et al. · Annals of Oncology
Clinical practice evaluation of opioids induced constipation management in oncologic patients: The EIO-50 project
2018 · J. Salvador Bofill, V. Guillem Porta, et al. · Annals of Oncology
The future of precision medicine, strengths and weaknesses: An expert position paper.
2018 · Vicente Guillem Porta, Antonio Anton, et al. · Journal of Clinical Oncology
How do Spanish medical oncologists manage breakthrough pain? A national study
2017 · E. Aranda, C. Camps Herrero, et al. · Annals of Oncology
Ganando la batalla al cáncer: logros y retos
2017 · V. Guillem Porta · Anales (Reial Acadèmia de Medicina de la Comunitat Valenciana)
Cuando una paciente con cáncer de mama metastásica luminal A es subsidiaria de quimioterapia en primera línea
2016 · Carmen Herrero Vicent, Abraham Hernández Blanquisett, et al. · Revista de Senología y Patología Mamaria
A Prognostic Index for Locoregional Recurrence (Lrr) After Neoadjuvant Chemotherapy (Nac)
2014 · C. Herrero-Vicent, A. Guerrero, et al. · Annals of Oncology
Works count: 33
Citation count: 901
H-index: 8
I10-index: 8
Year
Topic
Type